
Evolent Health (EVH) Stock Forecast & Price Target
Evolent Health (EVH) Analyst Ratings
Bulls say
Evolent Health Inc. demonstrates a robust growth outlook driven by its ability to cross-sell new services and expand risk-based product offerings, with the potential for the Aetna contract to generate over $2 billion in annual revenue. The company maintains a strong pipeline valued at $650 million, showcasing the highest momentum in its history, alongside consistent top-line growth that has exceeded its mid-teens revenue growth target. Additionally, the increasing prevalence of disease, particularly within specialty care areas such as oncology and cardiology, combined with favorable trends pushing towards value-based payment models, positions Evolent to capitalize on a substantial total addressable market and sustain demand for its innovative solutions.
Bears say
Evolent Health Inc faces a significant revenue decline as the company's non-enhanced revenue is projected to fall from approximately $285 million in 2025 to around $170 million in 2026 due to a shift in revenue mix. Additionally, management anticipates headwinds from a potential 65% decline in Health Insurance Exchange (HIX) membership and a 3% decrease in Medicare Advantage contracts, leading to an adjusted EBITDA forecast between $134 million and $144 million, which includes anticipated benefits from AI initiatives. These factors, combined with predictions of a 5% decline in Medicaid membership potentially dragging EBITDA down by $8 million to $10 million, contribute to a negative outlook on Evolent Health's stock.
This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.
Evolent Health (EVH) Analyst Forecast & Price Prediction
Start investing in Evolent Health (EVH)
Order type
Buy in
Order amount
Est. shares
0 shares